contains the active substance tocilizumab, which is a protein made from soecific immune cells (monoclonal antibody), that blocks the action of a specific protein (cytokine) called interleukin-6. IL-6 activity in body causes many symptoms of autoimmune disease such as Rheumatoid Arthtitis (RA). Blocking IL-6 receptors can reduce the inflammation in your body and reduce symptoms.
Temziva is used for:
Treat adults with moderate to severe active rheumatoid arthritis (RA), an autoimmune disease, who have either not responded adequately to, or who were intolerant to, previous therapy with other medicines used for treatment of RA. In this situation Temziva can be given alone or in combination with Methotrexate.
Treat active Systemic Juvenile Idiopathic Arthrits (sJIA) in children aged 2 years and over. Temziva can be given alone or in combination with Methotrexate.
Treat active Polyarticular Juvenile Idiopathic Arthritis (pJIA) in children aged 2 years and over. Temziva can be given alone or in combination with Methotrexate.
Treat Cytokine Release Syndrome (CRS) in adults and children aged 2 years and over. CRS is a side-effect in patients treated with chimeric antigen receptor (CAR) T-cell therapies used to treat certain types of cancer.
Treat Cytokine Release Syndrome (CRS) as the main danger cause of Corona disease in adult patients with confirmed diagnosis of covid-19.
Temziva has 2 dosage form: a Vial contains 400mg/20mg concentrate for solution for intravenous injection and a prefilled syringe contains 162 mg concentrate for solution for subcutaneous injection. The active substance is tocilizumab. Each 20ml vial contains 400mg tocilizumab (20mg.ml). Each pack contains 1 vial of concentrated solution, 1 alcoholic pad and 1 brochure for patient. Temziva is infused intravenously by the doctor or nurse. Drug solution id diluted by sodium chloride 9mg/ml (0.9%) solution for injection and injection and given through a drip in the vein (intravenous infusion) over one hour.
Temziva can be used to treat Cytokine Release Syndrome (CRS) as the main danger cause of Corona disease in adult patients with confirmed diagnosis of covid-19.
Biopharmaceutical production applying cutting edge biotechnology practices and manufacturing technology transfer
Increasing the quality and availability of biopharmaceutical products in order to improve quality of life of global community
Achieving the first rank in development, production and export of biopharmaceuticals in the region over the next 5 years
Winning 5% of Iran's market share over the next 5 year